Form 4: Provectus Biopharmaceuticals Director Acquires Convertible Promissory Note and Preferred Stock

Director Edward Pershing acquires an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Summary

• On March 26, 2024, Edward Pershing, a director of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note for $400,000.
• The note can be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.
• Pershing also acquired 139,763 shares of Series D-1 Convertible Preferred Stock.
• The total amount of Series D-1 Convertible Preferred Stock beneficially owned by Pershing is now $1,915,000.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.

Sentiment

Score: 6

Explanation: The sentiment is neutral. A director is investing in the company, which is generally positive, but the investment is in the form of convertible debt and preferred stock, which can have dilutive effects.

Positives

• A director's investment in the company may signal confidence in its future prospects.

Risks

• The conversion of preferred stock could dilute existing common shareholders.

Future Outlook

The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

This type of investment is common in the biopharmaceutical industry, especially for companies seeking funding for research and development.

Comparison to Industry Standards

• Convertible notes are a fairly standard method of financing for small cap biotech companies.
• Comparable companies such as Amgen, Gilead, and Biogen typically use more traditional debt or equity financing methods due to their larger size and established revenue streams.
• The terms of the convertible note, such as the interest rate and conversion price, would need to be compared to similar financings in the biotech sector to assess whether they are favorable to the company.

Stakeholder Impact

• Potential dilution of existing shareholders upon conversion of preferred stock to common stock.

Key Dates